Kymera Therapeutics (KYMR) Competitors $44.81 +0.28 (+0.63%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$44.81 0.00 (0.00%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMDShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Qiagen Viatris Ascendis Pharma A/S Moderna BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Kymera Therapeutics (NASDAQ:KYMR) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Is KYMR or QGEN more profitable? Qiagen has a net margin of 4.68% compared to Kymera Therapeutics' net margin of -409.07%. Qiagen's return on equity of 14.61% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-409.07% -30.11% -25.65% Qiagen 4.68%14.61%8.80% Does the media refer more to KYMR or QGEN? In the previous week, Kymera Therapeutics had 21 more articles in the media than Qiagen. MarketBeat recorded 28 mentions for Kymera Therapeutics and 7 mentions for Qiagen. Qiagen's average media sentiment score of 0.93 beat Kymera Therapeutics' score of 0.43 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, KYMR or QGEN? Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M61.99-$223.86M-$3.10-14.45Qiagen$1.98B5.43$83.59M$0.40120.85 Do analysts recommend KYMR or QGEN? Kymera Therapeutics presently has a consensus price target of $59.11, indicating a potential upside of 31.91%. Qiagen has a consensus price target of $49.40, indicating a potential upside of 2.19%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Kymera Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.00Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Which has more volatility & risk, KYMR or QGEN? Kymera Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Do insiders and institutionals believe in KYMR or QGEN? 70.0% of Qiagen shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryQiagen beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.92B$2.89B$5.49B$9.01BDividend YieldN/A2.43%5.38%4.09%P/E Ratio-14.4521.5627.4220.26Price / Sales61.99245.52407.97121.21Price / CashN/A41.9536.6357.47Price / Book3.477.518.085.67Net Income-$223.86M-$55.05M$3.16B$248.47M7 Day Performance1.56%4.59%2.81%3.29%1 Month Performance1.24%4.86%3.68%5.19%1 Year Performance48.57%5.82%35.29%21.35% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics3.1887 of 5 stars$44.81+0.6%$59.11+31.9%+48.6%$2.92B$47.07M-14.45170Analyst ForecastInsider TradeQGENQiagen4.0679 of 5 stars$48.07+0.6%$49.40+2.8%+22.5%$10.62B$1.98B120.525,765Dividend AnnouncementVTRSViatris3.2803 of 5 stars$8.93-0.9%$10.40+16.5%-10.9%$10.57B$14.74B-2.8232,000ASNDAscendis Pharma A/S3.6797 of 5 stars$172.60+0.2%$220.67+27.8%+29.7%$10.53B$393.54M-27.481,017Analyst ForecastMRNAModerna4.391 of 5 stars$27.59+1.6%$46.61+68.9%-73.7%$10.50B$3.24B-3.165,800Options VolumeBBIOBridgeBio Pharma4.7106 of 5 stars$43.18-3.7%$58.85+36.3%+74.8%$8.52B$221.90M-12.23400Insider TradeAnalyst RevisionHigh Trading VolumeBPMCBlueprint Medicines1.7469 of 5 stars$128.18+0.1%$128.06-0.1%+17.6%$8.27B$508.82M-51.89640VRNAVerona Pharma PLC American Depositary Share2.6669 of 5 stars$94.58+0.8%$101.10+6.9%+480.4%$7.99B$42.28M-47.2930Positive NewsAnalyst ForecastROIVRoivant Sciences1.9619 of 5 stars$11.27-1.1%$17.50+55.3%+3.5%$7.74B$29.05M-45.08860ELANElanco Animal Health2.2634 of 5 stars$14.29flat$15.17+6.1%+3.6%$7.10B$4.44B19.319,000Analyst ForecastRVMDRevolution Medicines4.5752 of 5 stars$36.79-0.3%$67.58+83.7%+0.2%$6.88B$11.58M-9.20250Analyst Revision Related Companies and Tools Related Companies QGEN Competitors VTRS Competitors ASND Competitors MRNA Competitors BBIO Competitors BPMC Competitors VRNA Competitors ROIV Competitors ELAN Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
